A PHARMACOKINETIC AND PHARMACOGENETIC STUDY OF ALISERTIB COMBINED WITH IRINOTECAN AND TEMOZOLOMIDE IN CHILDREN AND ADOLESCENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA.

被引：0
|
作者：
Kudgus, R. A. [1 ]
Fox, E. [2 ]
McGovern, R. M. [1 ]
Moorthy, G. [2 ]
Marachelian, A. [3 ]
DuBois, S. G. [4 ]
Reid, J. M. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[3] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-031
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [21] Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults
    Ju, Hee Young
    Park, Meerim
    Lee, Jun Ah
    Park, Hyeon Jin
    Park, Seog Yun
    Kim, June Hyuk
    Kang, Hyun Guy
    Yang, Hee Chul
    Park, Byung-Kiu
    CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 563 - 571
  • [22] Phase 1 Trial of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors: A Children's Oncology Group Study
    Bagatell, Rochelle
    Norris, Robin
    Ingle, Ashish M.
    Ahern, Charlotte
    Voss, Stephan
    Fox, Elizabeth
    Little, Anthony R.
    Weigel, Brenda J.
    Adamson, Peter C.
    Blaney, Susan
    PEDIATRIC BLOOD & CANCER, 2014, 61 (05) : 833 - 839
  • [23] Phase I study of oral irinotecan and temozolomide in children with relapsed high-risk neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) Consortium study
    Wagner, L. M.
    Villablanca, J. G.
    Stewart, C. F.
    Crews, K. R.
    O'Shaughnessy, M. A.
    Groshen, S.
    Reynolds, C. P.
    Park, J. R.
    Maris, J. M.
    Matthay, K. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Phase I Trial of Oral Irinotecan and Temozolomide for Children With Relapsed High-Risk Neuroblastoma: A New Approach to Neuroblastoma Therapy Consortium Study
    Wagner, Lars M.
    Villablanca, Judith G.
    Stewart, Clinton F.
    Crews, Kristine R.
    Groshen, Susan
    Reynolds, C. Patrick
    Park, Julie R.
    Maris, John M.
    Hawkins, Randall A.
    Daldrup-Link, Heike E.
    Jackson, Hollie A.
    Matthay, Katherine K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (08) : 1290 - 1296
  • [25] Vincristine, irinotecan, and temozolomide as a salvage regimen for relapsed or refractory sarcoma in children and young adults.
    Park, Byung-Kiu
    Ju, Hee Young
    Park, Meerim
    Park, Hyeon Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] MOLECULAR RADIOTHERAPY WITH MATIN: IODINE-131 META-IODOBENZYLGUANIDINE AND TOPOTECAN IN NEUROBLASTOMA. TOXICITY AND SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA. A SIOPEN STUDY
    Gaze, Mark N.
    Bomanji, Jamshed B.
    Brock, Penelope R.
    Flux, Glenn D.
    Lacerda, Ana
    Mairs, Robert J.
    Saran, Frank H.
    Staudenherz, Anton
    Uyttebroeck, Anne
    Ladenstein, Ruth
    PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1058 - 1058
  • [27] Temozolomide versus Irinotecan-Temozolomide for Children with Relapsed and or Refractory High-Risk Neuroblastoma (RR-HRNB). Results of the Beacon-Neuroblastoma Randomized Phase II Trial, an ITCC-SIOPEN Trial
    Moreno, L.
    Moroz, V.
    Owens, C.
    Valteau-Couanet, D.
    Gambart, M.
    van Eijkelenburg, N.
    Zwaan, C. M.
    Castel, V.
    Murphy, D.
    Morland, B.
    Gray, J.
    Marshall, L.
    Burchill, S.
    Chesler, L.
    Peet, A.
    Schleiermacher, G.
    Fenwick, N.
    Kearns, P.
    Pearson, A.
    Wheatley, K.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S34 - S34
  • [28] Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma
    Larrosa, Crstina
    Simao Rafael, Margarida
    Pablo Munoz, Juan
    Gorostegui, Maite
    Castaneda Heredia, Alicia
    Garraus, Moira
    Mora, Jaume
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Toxicity of 131I-MIBG combined with high-dose chemotherapy in children with refractory neuroblastoma.
    Amoroso, L.
    Villavecchia, G.
    Cabria, M.
    Piccardo, A.
    Conte, M.
    Nantron, M.
    Garaventa, A.
    De Bernardi, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] IRINOTECAN AND TEMOZOLAMIDE FOR CHILDREN WITH RELAPSED OR REFRACTORY RHABDOMYOSARCOMA, NEUROBLASTOMA AND EWING SARCOMA TUMORS: EXPERIENCE IN A SINGLE CENTER
    Gil, Gimena
    Cores, Maria
    Detoni, Deborah
    Puppa, Gabriela
    Garcia Lombardi, Merce
    Rey, Guad
    PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1093 - 1094
12345